Italia markets closed

Saniona AB (publ) (0RQJ.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
2,8450+0,0350 (+1,25%)
Alla chiusura: 04:24PM BST
Schermo intero
Chiusura precedente2,8100
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno2,8450 - 2,8450
Intervallo di 52 settimane2,8450 - 2,8450
Media VolumeN/D
Beta (5 anni mensile)0,51
Rapporto PE (ttm)N/D
EPS (ttm)-7,3900
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model

    PRESS RELEASE June 24, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that professor Helle Prætorius, Univ. of Aarhus, Denmark, made a presentation at the ECM conference, 2022, which shows that SAN903 protects against fibrosis in a chronic kindney dease model. Chronic kidney disease (CKD) is a devastating, progressive deterioration of renal function that significantly impacts the quality of life for the individual and represents a substantial cost for the

  • GlobeNewswire

    Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022

    PRESS RELEASE May 25, 2022 Today, on May 25, 2022, the annual shareholders’ meeting was held in Saniona AB. The annual shareholders’ meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes. Resolution on adoption of accounts and distribution of the company’s result for 2021 The annual shareholders’ meeting resolved to adopt the profit and lo

  • GlobeNewswire

    Saniona publishes its interim report for the first quarter of 2022

    Q1 2022 (Q1 2021) Revenue was SEK 6.6 M (3.4 M)Operating loss was SEK -133.2 M (-94.1 M)Net loss was SEK -133.4 M (-83.4 M)Loss per share was SEK -2.14 (-1.34)Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD) stage and the Positron Emission Tomography (PET) stage of its Phase 1 trial of SAN711; The ongoing Phase 1 trial is placebo-controlled, and the data remain blinded. Saniona continues to expect data from the trial